Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib
Treatment with the tyrosine kinase inhibitor imatinib is the standard of care for newly diagnosed patients with chronic myeloid leukemia. In recent years, several second-generation inhibitors – such as dasatinib and nilotinib – have become available: these promise to overcome some of the mutations a...
| Published in: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2014-11-01
|
| Online Access: | https://haematologica.org/article/view/7198 |